Abstract. Hypoxia is an important factor that results in failure of chemotherapy for the majority of solid tumor types, particularly for gastric cancer. In the present study, mesenchymal stem cells (MSCs), which have the ability to migrate to cancer tissues were used as a vehicle to supply oxygen to gastric cancer. The hemoglobin genes were transfected into MSCs as MSC-hemo groups. Subsequently, MSC-hemo groups were induced by isopropyl-b-D-thiogalactopyranoside and hemin to express hemoglobin. The hemoglobin was detected by western blotting method. Following this, the MSC-hemo groups were placed in an atmosphere containing 100% oxygen and were used to investigate the effect of the function of the oxygen-laden MSC-hemo group on gastric cancer chemotherapy with an MTT assay. As a first approach to investigate the possibility of MSCs as a vehicle to supply oxygen to anoxic cancer types, including gastric, liver, breast cancer, the results indicated that the oxygen-laden MSC-hemo group significantly enhanced the effect of chemotherapeutic treatments on gastric cancer cells. Utilizing MSCs as a vehicle to supply oxygen to the solid tumor may be a novel method to improve the hypoxia conditions of tumor tissues and improve the effect of chemotherapy on tumor cells.

Introduction

In 2012, gastric cancer was the most common malignancy globally, particularly in Eastern Asia (1). Additionally, in 2010, it was the second most common cancer and third most common cause of cancer-associated mortalities in China (2). The conventional therapies of gastric cancer, including chemotherapy and radiotherapy, have notable difficulties directly associated with hypoxia (3). Hypoxia occurs in solid tumor types, including gastric, liver, breast, pancreatic cancer, as a result of an inadequate supply of oxygen, due to exponential cellular proliferation and inefficient vascular supply; therefore, it is an adverse prognostic indicator in cancer as it is associated with resistance to radiotherapy and chemotherapy (4). The mechanisms of hypoxia-induced chemotherapy resistance are complex (5-8) due to hypoxia inducible factor-1 (HIF-1) acting as a transcription factor to upregulate numerous genes with varying functions, including the regulation of drug efflux, proliferation, angiogenesis and metabolic changes (9,10). Improving the hypoxia condition can significantly enhance the effect of gastric cancer chemotherapy (11).

With profound progress in biomedical science, numerous targeted therapeutic methods have been investigated in a number of cancer types, including gastric cancer (12). In this aspect, mesenchymal stem cells (MSCs) have a notable potential as a tool for targeted therapy, due to these cells being easily transduced in vitro and can be used as gene-delivery vehicles for gene therapy (13). To date, a large number of genes with tumor-suppressive functions have been successfully engineered into MSCs and have been tested in a number of cancer models, including interferon-α (IFN-α) in melanoma (14), IFN-γ in leukemia (15), interleukin-12 in cervical cancer (16,17), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in breast and hepatocellular carcinoma (18,19). In the present study, the aim was to produce hemoglobin protein-expressing MSCs, and then to use these MSCs as a vehicle to supply oxygen to the hypoxic gastric cancer cells. Additionally, whether this method could enhance the effect of gastric cancer chemotherapy was investigated.

Materials and methods

Cell culture. Gastric cancer cell lines MKN-45 and SGC-7901 were preserved by the Key Laboratory of Digestive System Tumors. The cells were cultured in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The culture was maintained in a humidified atmosphere of 5% CO2 at 37°C.
Tumors, Lanzhou University Second Hospital (Lanzhou, China). The gastric cancer cell lines were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) in a humidified atmosphere containing 5% CO2 at 37°C. MSCs from bone marrow were preserved by the Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital and cultured in low-glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS in a humidified atmosphere containing 5% CO2 at 37°C. Subsequently, the morphology of the cultured cells was observed with a light inverted phase-contrast microscope (Nikon TS-100F; x20).

**Plasmid construct.** The hemoglobin subunit α2 (HBA2) and hemoglobin subunit β (HBB) genes were chemically synthesized by GenePharma Gene Technology, Co., (Shanghai, China). The sequences of HBA2 and HBB are located on GeneBank (https://cipotato.org/genebankcip/). Subsequently, the products were ligated with linearized pEX-2 Vector (GenePharma Gene Technology, Co., Shanghai, China; concentration, 500 ng/ml) using T4 DNA ligase (Takara Bio, Inc., Otsu, Japan) at 22°C for 60 min. The recombinant plasmids were transformed into Top 10 competent cells with the CaCl2 method (20). To identify the positive clones, plasmids were extracted with a mini-plasmid preparation kit (Takara Bio, Inc.) according to the manufacturer’s instructions. The sequences of HBA2 and HBB were amplified from the extracted plasmids using primers (forward primer, 5’-TCAGGCTAGACATGGTTTC-3’; and reverse primer, 5’-CTCTACATTGCCAAAAGCACG-3’). This was conducted the next day after transfection. Construction plasmid helper-SL3 and envelope plasmid helper-SL4 were also purchased in GenePharma Gene Technology, Co. GFP report gene was added to mark the positive cells.

**Lentivirus packaging.** 293T cells (Genomeditech, Shanghai, China) were preserved by Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital, and maintained with high-glucose DMEM (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS. The 293T cells at 90% confluence were used for lentivirus packaging. The plasmid of pEX-2 containing the hemoglobin gene coding sequence, the construction plasmid helper-SL3 and the envelope plasmid helper-SL4 were co-transfected (5 µl/1x105 cells) into 293T cells mediated by Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). After 72 h, the culture medium containing packaged lentivirus particles were collected, filtered and stored at -80°C for further processing. The lentiviral titer was detected by cell counting using a fluorescent microscope (magnification, x40).

**Effect of the function of oxygen-laden MSC-hemo cells on gastric cancer cell chemotherapy.** A Transwell assay was conducted, and because GFP report gene was involved in the lentivirus particles, the results were observed with an fluorescence microscope (x40). In the present study, two chemotherapeutics,
5-fu and CDDP, were tested. For these chemotherapeutics, three interventions were set: Only chemotherapeutic intervention, as a control group; chemotherapeutic and non-transformed MSC interventions; and chemotherapeutic and oxygen-laden MSC-hemo interventions. These chemotherapeutics were investigated in two different gastric cancer cell lines, MKN45 and SGC-7901. The interventions were conducted as follows: Gastric cancer cells (MKN45 or SGC-7901) were seeded (1x10^5 cells/well) in the lower well of Transwell plates (Corning Costar, Cambridge, MA, USA), which were 6.5 mm in diameter with 8 µm pore filters and contained 600 µl DMEM (Gibco; Thermo Fisher Scientific, Inc.). Chemotherapeutics (2 mg/ml 5-fu or 0.4 mg/ml CDDP) were added into every plate of all tested groups. For the oxygen-laden MSC-hemo group, the cells were suspended in serum-free DMEM (Gibco; Thermo Fisher Scientific, Inc.) and seeded (1x10^5 cells/well) in the upper well of Transwell plates, and then they were placed in an atmosphere containing 100% oxygen. For the control group, 0.9% NaCl was added in the upper well of the Transwell plates. Furthermore, for the group containing the non-transformed MSCs, MSCs were suspended in serum-free DMEM and seeded (1x10^5 cells/well) in the upper well of the Transwell plates. Subsequently, the upper wells were placed on the lower wells. Following culturing for 24 h in a humidified atmosphere containing 5% CO_2 at 37°C, the cells in the lower wells were collected to conduct an MTT assay, in order to assess the effect of the three different interventions.

**5TT assay.** An MTT assay was conducted as described subsequently. MTT powder (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was dissolved (final concentration, 5 mg/ml) in PBS and filtered. MTT solution was added to the cells on plates and incubation continued for 4 h at 37°C. Supernatants were removed and 200 µl 0.04 M HCl in isopropanol was added to each well. Optical densities were measured at 450 nm using Varioskan Flash (Thermo Fisher Scientific, Inc.) as the detection system. MTT assays were conducted in triplicate.

**Statistical analysis.** SPSS v17.0 was used to analyze data (SPSS, Inc., Chicago, IL, USA). Data were expressed as the mean ± standard deviation. Results were analyzed using one-way analysis of variance (ANOVA) to assess the statistical significance of overall differences between all treatment groups and to evaluate the MTT assay data. When the ANOVA test determined a value of P<0.05, data were further analyzed with the Student's Newman-Keuls-q test, in order to assess the statistical differences between every two groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Morphology of cultured cells.** As depicted in Fig. 1A, after culturing for 48 h, the MSCs grew in a fibroblast-like shape, >80% of the cells fused together. Additionally, the
Figure 2. Identification results of the recombinant vector. (A) The structure of pEX-2. (B) The sequences of hemoglobin genes expressed in the recombinant vector. The result demonstrated that the sequence was consistent with (Ba) NM_000517 (HBA2).
gastric cell lines MKN45 and SGC-7901 also exhibited normal characteristics of gastric cancer cells, as depicted in Fig. 1B.

Identification of the recombinant vector. The structure of pEX-2 is depicted in Fig. 2A. The expression of hemoglobin genes in the recombinant vector was identified by sequencing, and the result demonstrated that the sequence was consistent with NM_000517 (HBA2) and NM_000518 (HBB) in Genebank (Fig. 2B).

Screening of stable positive-infected MSC clones by fluorescent microscopy. The titer of the lentiviral particles was determined to be 1x10^9 TU/ml. MSCs were infected by lentiviral particles in DMEM with 5 µg/ml polybrene. After 72 h infection by lentiviral particles, GFP could be observed by fluorescent microscopy in the MSC-hemo-GFP and MSC-GFP groups. No GFP expression was observed in the blank control group (Fig. 3).

Observing the expression of hemoglobin with western blotting. Subsequently, MSCs were infected with the constructed lentiviral vectors, and the expression of hemoglobin was detected with western blotting. As depicted in Fig. 4, hemoglobin was detected in the MSC-hemo (Lane 3) and positive control groups (Lane 2); however, hemoglobin protein was not expressed in the empty MSC control group (Lane 1).

Effect of oxygen-laden MSC-hemo function on the gastric cancer cell chemotherapy. The effect of oxygen-laden MSC-hemo function on the gastric cancer cell chemotherapy was assessed with an MTT assay. As depicted in Fig. 5, compared with the 5-fu treatment group (Fig. 5A), the oxygen-laden MSC-hemo group significantly enhanced the effect of 5-fu treatment on MKN45 and SGC-7901 cells (P<0.05), while the non-transformed MSC and 5-fu group had no significant difference with the control group. In the CDDP treatment...
group (Fig. 5B), the identical results were produced. This data indicated that the oxygen-laden MSC-hemo group may contribute to the effect of the function of chemotherapeutics on gastric cancer cell chemotherapy.

Discussion

Hypoxia is an integral characteristic of the tumor microenvironment and a well-documented source of therapeutic failure in clinical oncology (21). It is a direct result of a lack of oxygen, which is caused by microvascular defects that accompany the accelerated neoplastic growth and indirectly caused by alterations in the proteome/genome, angiogenesis and pH changes (4). The majority of solid tumor cases >1 mm³ in volume contain regions of hypoxia, particularly gastric cancer (22). The stomach is a hollow organ located deep within the enterocelia, and hypoxia is more severe for gastric cancer (23).

Solid cancer types with hypoxia-induced phenotypes are frequently resistant to chemotherapy and have a poor prognosis (24). In particular, cancer cells with reduced levels of oxygenation are more resistant to a number of chemotherapeutic agents, including 5-fu and CDDP (25). This cellular response to hypoxia, primarily mediated by HIF-1, may increase the aggressiveness of cancer cells and contribute to poor responses to treatment (26). With regards to the resistance of gastric cancer cells to 5-fu, Nakamura et al (27) reported that the expression of HIF-1α in gastric cancer tissue was an independent prognostic factor in patients who were administered 5-fu
adjuvant treatment following resection. These authors also demonstrated that transfection of the HIF-1α gene into gastric cancer cells increased their resistance to 5-fu in vitro and in vivo. Xuan et al (3) also confirmed that in the MKN45 and AGS cell lines, HIF-1α expression is dependent on hypoxic conditions and that the genetic enhancement of HIF-1α under normoxic or hypoxic conditions can eliminate the sensitivity to 5-fu. Improvement of hypoxia in cancer is therefore a prime target for the development of novel gastric cancer therapeutics. Reduced treatment dosages and increased benefits for the patient are envisaged as a consequence of these investigations. In conclusion, the ability to increase oxygenation of tumors will revolutionize contemporary cancer treatment. Successful treatment of hypoxic cells has the potential to not only improve local control but also impact overall patient survival.

Generally, oxygen is transported in the blood by hemoglobin (28). Recombinant human erythropoietin (rhEPO) is currently administered to patients with cancer, in order to protect against chemotherapy or tumor-associated anemia, and clinical trial results indicate numerous beneficial effects of rhEPO treatment on the therapeutic outcome of patients (29). In the present study, a novel method was developed to increase the oxygen supply for the gastric cancer cells to overcome the therapeutic resistance of MKN45 and SGC-7901 cell lines to 5-fu and CDDP.

MSCs are a type of marrow stroma cells, which exist in numerous tissues and are easy to obtain and amplify. Examples include the bone marrow, umbilical cord blood and umbilical cord (30). Due to their notable differentiation potential, they are used in regenerative medicine (31). In the last decade, increasing numbers of researchers have determined another beneficial characteristic of MSCs, that MSCs are able to home in on tumor sites (32-34). This means that MSCs are ideal vehicles for targeted gene therapies. At the same time, MSCs can avoid immune rejection (35,36), which provides further convenience for the use of MSCs as a tool for targeted therapy. In the present study, MSCs were used as a vehicle for hemoglobin, with MSCs infected by lentivirus vectors delivering the HBA2 and HBB genes. Additionally, the present results demonstrated that these MSC-hemo cells could continuously release hemoglobin protein following induction with IPTG and hemin. Following placing in an atmosphere containing 100% oxygen, the effect of MSC-hemo on gastric cancer chemotherapy was evaluated. A total of two groups were set according to the therapeutic drugs used (5-fu or CDDP). Subsequently, three different intervention measures were conducted on MKN45 and SGC-7901 cells in every group. The first intervention measure was 0.9% NaCl and the therapeutic drug as a control, the second measure was non-transformed MSCs and the therapeutic drug and the final measure was the oxygen-laden MSC-hemo group and the therapeutic drug. The results depicted in Fig. 5 indicated that the oxygen-laden MSC-hemo group could significantly improve the effect of chemotherapy, compared with the control group and the non-transformed MSC group (P<0.05). Furthermore, the non-transformed MSC+5-fu or MSC+CDDP groups demonstrated no significant difference with the control group (P>0.05). These results indicated that this method can successfully supply oxygen to the gastric cancer cells and enhance the effect of chemotherapeutics. This provides a novel method of thinking to reduce the resistance to chemotherapy of gastric cancer and improve the overall patient survival in clinical work. Furthermore, this is the initial step and this requires further study to test this method in vivo and in preclinical experiments.

To conclude, improving the tumor hypoxia environment could provide notable benefit for cancer treatments, particularly for gastric cancer. Using MSCs as a vehicle carrying oxygen to the tumor microenvironment is a direct and effective method. With the profound progress of biomedical science, targeted therapy had been improved in the technology and security aspects (37). The present study demonstrated the potential of MSCs as an effective delivery system that targets tumors and reduces the resistance of anticancer drugs. This may represent a prospective method for the treatment of gastric cancer types.

Acknowledgements

The authors would like to thank Professor Liang Qiao (University of Sydney, Sydney, Australia) for his suggestions.

Funding

This study was partly supported by the National Natural Science Foundation of China (grant no. 31270532).

Availability of data and materials

The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

YL conceived and designed the study. YZ was a major contributor in acquiring data, data analysis and writing the manuscript. WH helped with the acquisition of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


